Cargando…
CD4(+) T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma
Lenalidomide modulates the host immune response against myeloma via multiple actions. Although these effects have been elucidated in vitro, the central action of lenalidomide-mediated anti-myeloma immune response in vivo is not clear. To investigate its immune action in vivo, we selected the murine...
Autores principales: | Zhang, Liang, Bi, Enguang, Hong, Sungyoul, Qian, Jianfei, Zheng, Chengyun, Wang, Michael, Yi, Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742159/ https://www.ncbi.nlm.nih.gov/pubmed/26447613 |
Ejemplares similares
-
Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma
por: Li, Rong, et al.
Publicado: (2020) -
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012) -
Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013) -
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018) -
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)